

## Influence of a Regular, Standardized Meal on Lipid Profile of People with Diabetes

Susana Garrido<sup>1</sup>, Fernando Pichel<sup>1</sup>, Helena Neto<sup>1</sup>, Helena Ramos<sup>1</sup>, José Carlos Oliveira<sup>2</sup> and Isabel Palma<sup>1</sup>

<sup>1</sup>Division of Metabolism, Endocrinology and Diabetes, Hospital de Santo António, Centro Hospitalar do Porto, Portugal

<sup>2</sup>Division of Clinical Chemistry, Hospital de Santo António, Centro Hospitalar do Porto, Portugal

\*Corresponding author: Susana Garrido, Serviço de Endocrinologia, Diabetes e Metabolismo, Hospital de Santo António, Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 - Porto, Portugal, Tel: 00351 22 207 7500; E-mail: scgarrido@gmail.com

Received date: June 09, 2015, Accepted date: September 14, 2015, Published date: September 21, 2015

Copyright: © 2015 Garrido S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

**Aims:** The need to fast before lipid screening has been questioned in the past years. The aim of this study was to determine the influence of a light meal on the lipid profile in people with diabetes.

**Methods:** 115 participants with type 2 diabetes were recruited between April/2013-August/2014 from our Outpatient Diabetes Education Clinic. Clinical and analytical evaluation took place in 2 moments (8-hour fasting= $t_0$ ; 2h after a light standardized meal= $t_1$ ), with measurements of total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides.

**Results:** Triglycerides concentration increased between the 2 moments (median difference  $t_1-t_0=0.07$  mmol/L,  $p=0.002$ ) but the total cholesterol, LDL-cholesterol, HDL-cholesterol and non HDL- cholesterol did not change significantly. Performing an analysis according to the LDL-cholesterol therapeutic goals proposed by Adult Treatment Panel III, we found an agreement between fasting and postprandial assessments of 91.1% for the goal of 2.6 mmol/L (102/112), and of 97.3% for the goal of 1.8 mmol/L (109/112). The same analysis was performed for the secondary goal, non HDL-cholesterol.

**Conclusion:** The data presented suggest that the nonfasting lipid profile can be an alternative to the fasting lipid profile in selected patients. Larger studies are needed to confirm these results and demonstrate an association of nonfasting lipemia and cardiovascular risk in individuals with diabetes.

**Keywords:** Diabetes; Lipid metabolism; Fasting

### Abbreviations:

ATP III: Adult Treatment Panel III; HDL-C: HDL Cholesterol; LDL-C: LDL Cholesterol; nonHDL-C: non-HDL Cholesterol; TG: Triglycerides; TC: Total Cholesterol

### Introduction

The plasma concentration of LDL cholesterol (LDL-C) is a recognized cardiovascular disease risk factor [1-3]. The studies that address this question are mainly based on fasting samples, and these are the current recommendations of most international societies [1,2,4-7].

Since humans spend most of their time in the nonfasting state and the postprandial lipemia has shown to be useful in the cardiovascular disease risk prediction [8-10], the need to fast before lipid screening has recently been questioned [8,11,12]. Moreover, nonfasting levels of lipids seem to differ only minimally from levels in the fasting state, both in the general population [8,13] and in individuals with diabetes [11]. Allaying these facts to the practical benefit of measuring the lipid profile in the postprandial state, the Danish national recommendation is, since 2009, for nonfasting assessment of LDL-C [14].

The aim of our work was to determine the influence of a light meal on the lipid profile in individuals with diabetes.

### Methods

A total of 115 consecutive participants with type 2 diabetes were included, recruited between April/2013 and August/2014 from the Outpatient Diabetes Education Clinic of Hospital de Santo António, Centro Hospitalar do Porto. All participants were similarly evaluated. Blood samples were drawn in 2 moments for measurements of total cholesterol (TC), LDL cholesterol, HDL cholesterol (HDL-C) and triglycerides (TG). The first blood sample was collected between 08:30 and 09:00 am after an 8 hour overnight fast ( $t_0$ ) and the second blood sample was collected 2 hours after a light meal ( $t_1$ ), containing standardized amounts of carbohydrates, protein and lipids. This meal included bread with ham or butter and coffee with milk (240-250 kcal; fat -17 g, protein -9-12 g and carbohydrates -134 g). No food or drinks, apart from water, were allowed to be ingested between the two blood collections. The measurements were made in the same laboratory, by standard hospital assays - CT, HDL-C e TG through enzymatic methods (Roche) in freshly drawn lithium-heparin plasma samples. LDL-C was calculated using the Friedewald Equation ( $LDLC=TC-HDLC-[TG/5]$ ) if TG levels <400 mg/dl and measured directly at higher levels [15]. Non-HDL cholesterol (nonHDL-C) was also calculated ( $TC-HDLC$ ). Because of its influence on lipid profile, we excluded thyroid dysfunction in all participants through TSH

measurement by electrochemiluminescence at  $t_0$ . Duration of diabetes was self-reported; hypertension was self-reported disease or use of antihypertensive medication; smokers were active smokers. Written informed consent was obtained from all patients.

The analysis of the data was conducted by using SPSS v20. LDL-C and nonHDL-C levels showed a normal distribution, unlike TC, TG and HDL-C. Comparison between the 2 moments were carried out by use of paired samples t-test (LDL-C and nonHDL-C) and Wilcoxon test (TC, TG, HDL-C). Paired LDL-C samples of participants with TG levels above 400 mg/dl were excluded from the analysis (n=3).

Furthermore, we analyzed the data according to the Adult Treatment Panel III (ATP III) fasting LDL-C goals: we investigated the proportion of participants with LDL-C at  $t_0 \geq 2.6$  mmol/L and LDL-C at  $t_1 < 2.6$  mmol/L and vice versa. We made a similar analysis using the cutpoint of 1.8 mmol/L and the secondary goal, nonHDL-C (1).

### Results

The characteristics of the individuals included in the study are shown in Table 1. TG concentration increased between the 2 moments (median difference  $t_1 - t_0 = 0.07$  mmol/L,  $p = 0.002$ ) but the TC, HDL-C, LDL-C and non-HDL-C did not change significantly (Table 2).

<b>Female (%)</b>	<b>50.4%</b>
Age (years)	57 (13; 40-79)
Duration of diabetes (years)	8.0 (11; 1-38)
HbA1c (%.mmol/mol)	8.3% (2.7; 4.8-14.0); 67 mmol/mol (9; 29-130)
Hypertension (%)	75%
Smoking habits (%)	8.8%
Body mass index (kg/m <sup>2</sup> )	29.0 (5.2; 19.3-44.0)
Statin therapy (%)	66.3%
Fibrate therapy (%)	17.3%

**Table 1:** Characteristics of the study population. Continuous variables are shown as median (interquartile range, minimum-maximum).

	<b>Fasting measurement (<math>t_0</math>)</b>	<b>Postprandial measurement (<math>t_1</math>)</b>	<b>Difference <math>t_1 - t_0</math></b>	<b>p</b>
TC (mmol/L) <sup>†</sup>	4.4 (1.2; 2.4-7.3)	4.4 (1.2; 2.4 - 7.3)	0.0 (0.2; -0.6 - 0.5)	0.74
TG (mmol/L) <sup>†</sup>	1.4 (0.8; 0.4-4.5)	1.5 (0.9; 0.5-4.2)	0.1 (0.3; -1.1 - 0.9)	0.002
HDL-C (mmol/L) <sup>†</sup>	1.2 (0.5; 0.4-2.6)	1.2 (0.5; 0.4-2.4)	0.0 (0.1; -0.3 - 0.2)	0.77
LDL-C (mmol/L) <sup>*</sup>	2.5 (0.8)	2.5 (0.8)	-0.03 (0.2)	0.06
nonHDL-C (mmol/L) <sup>*</sup>	3.3 (0.9)	3.3 (0.9)	0.0 (0.1)	0.89

**Table 2:** Fasting and 2 hour postprandial lipid values. <sup>†</sup>data presented as median (interquartile range, minimum-maximum); <sup>\*</sup> data presented as mean (standard deviation).

When we performed the same analysis by gender, the results were similar, except for HDL-C in men, where HDL-C decreased  $0.02 \pm 0.07$  mmol/L ( $p = 0.03$ ). We also analyzed the results according to the use of statins. The results obtained in the subgroup taking statins were similar to those of the overall sample, with an increase of TG concentration between the two moments (median 0.03 mmol/L, interquartile range 0.4 mmol/L, minimum -3.0 mmol/L, maximum 0.9 mmol/L;  $p = 0.03$ ); in the remaining parameters analyzed there were no statistically significant changes (data not shown). Given the small number of participants taking fibrates that sub analysis was not done.

		<b>Postprandial (mmol/L)</b>					<b>Postprandial (mmol/L)</b>		
		$\geq 2.6$	$< 2.6$	<b>Total</b>			$\geq 1.8$	$< 1.8$	<b>Total</b>
<b>Fasting (mmol/L)</b>	$\geq 2.6$	49	5	54	<b>Fasting (mmol/L)</b>	$\geq 1.8$	88	3	91
	$< 2.6$	5	53	58		$< 1.8$	3	18	21
	<b>Total</b>	54	58		<b>Total</b>	91	21		

**Table 3:** LDL-C according to the 2 therapeutic goals proposed by ATP III.

Table 3 shows the analysis according to the two therapeutic goals for LDL-C proposed by ATP III. We also present the data concerning the secondary goal, nonHDL-C (Table 4).

		<b>Postprandial (mmol/L)</b>					<b>Postprandial (mmol/L)</b>		
		$\geq 3.4$	$< 3.4$	<b>Total</b>			$\geq 2.6$	$< 2.6$	<b>Total</b>
<b>Fasting (mmol/L)</b>	$\geq 3.4$	47	3	50	<b>Fasting (mmol/L)</b>	$\geq 2.6$	85	0	85
	$< 3.4$	3	62	65		$< 2.6$	3	27	30
	<b>Total</b>	50	65		<b>Total</b>	88	27		

**Table 4:** nonHDL-C according to the 2 therapeutic goals proposed by ATP III.

Considering the LDL-C cut-off of 2.6 mmol/L, fasting and postprandial assessments agreed on classification for 91.1% of the participants (102/112). The proportion of participants with LDL-C  $\geq 2.6$  mmol/L was similar in the two assessments (49/54). Postprandial results inappropriately classified participants with borderline values, with small differences between the two measurements (between 0.1 and 0.4 mmol/L). Considering the LDL-C cut-off of 1.8 mmol/L, fasting and postprandial assessments agreed on classification for 97.3% of the participants (109/112). Also here the differences between the two measurements were small (between 0.2 and 0.3 mmol/L).

Regarding the nonHDL-C, and considering the cut-off of 3.4 mmol/L, fasting and postprandial assessments agreed on classification for 94.8% of the participants (109/115). The proportion of participants with discordant results was similar in the two assessments (88/91). Postprandial results inappropriately classified participants with borderline values, with small differences between the two

measurements (between 0.1 and 0.2 mmol/L). Considering the nonHDL-C cut-off of 2.6 mmol/L, fasting and postprandial assessments agreed on classification for 97.4% (112/115). Also in this scenario the differences between the two measurements were small, between 0.1 and 0.3 mmol/L.

## Discussion

We found that levels of lipids don't change (TC, HDL-C, LDL-C and nonHDL-C) or change only modestly (TG) in response to a light meal in individuals with diabetes. Statin use or gender did not appear to be influential.

The assumption that the lipid profile varies significantly between the fasting and the nonfasting state is based on studies using oral fat tolerance tests [15,16] and extremely high fat meals [17]. However, both our findings and others' demonstrate that, after a normal meal, the lipid concentrations differ only slightly compared to fasting [8,13,18], even in individuals with diabetes [11], because most people consume much less fat at ordinary meals. It should be considered whether these differences are of clinical importance, especially considering that there are other factors, both analytical and physiological, that also influence levels of lipids [19].

Other argument often presented relates with the calculation of LDL-C using the Friedewald formula, which requires fasting TG measurement. Nonetheless, our results show no significant changes of calculated LDL-C in response to a light meal, despite the increase in TG, as previously demonstrated by Langsted et al [8,11].

In this study, the determination of the lipid profile, including LDL-C and nonHDL-C, in the postprandial period (2 hours after a light meal) allowed a correct classification of most participants in the appropriate risk groups and didn't incorrectly influenced the therapeutic decisions regarding dyslipidemic therapy.

Other of the arguments for the measurement of lipid profile in the fasting period is that the fasting requirement was applied in the majority of lipid-lowering trials [8]. However, more recent studies have focused on cardiovascular disease risk prediction and postprandial lipemia, with no evidence demonstrating that fasting lipid levels are superior to nonfasting levels for cardiovascular risk prediction [8,20]. Indeed, levels of nonfasting TG are as good or even better at predicting future cardiovascular events than levels of fasting TG [9,10,21]. Taking that into account, postprandial lipemia may be masked by measuring lipid profile in the fasting state, and fasting TG concentrations may not be optimal for evaluating cardiovascular risk in these participants [11].

The strengths of our study include using paired samples and a standardized meal, whereas most of previous studies used nonstandardized meals and/or unpaired samples. We do not consider the use of this standardized meal a limitation, since it included ingredients that are part of a regular Western diet. Despite that, we cannot make conclusions regarding other diets. In the same way, we can only draw conclusions about the variation between fasting and 2 hours after eating, because we didn't examine repeated measurements with differing fasting times.

These data point to the possibility of collecting blood samples until 2 hours after a light meal in patients with diabetes. This measure, if implemented, would simplify the blood sampling process, both for patients, practitioners and hospitals. The risk of hypoglycemia in individuals with diabetes with prolonged fasting cannot be neglected, as it is associated with high morbidity [22,23].

## Conclusion

The data presented, combined with other recent studies, suggest that the nonfasting lipid profile can be an alternative to the fasting lipid profile in selected patients. Larger studies are needed to confirm these results and to demonstrate an association of nonfasting lipemia and cardiovascular risk in people with diabetes.

## References

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 106: 3143-3421.
2. Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, et al. (2008) Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 93: 3671-3689.
3. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard B V, et al. (2008) Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. *J Am Coll Cardiol* 5: 1512-1524.
4. Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, et al. (2014) 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 63: 2889-2934.
5. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen M-R, et al. (2011) ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J* 32: 1769-1818.
6. American Diabetes Association (2014) Standards of Medical Care in Diabetes 2014. *Diabetes Care* 37 Suppl 1: S14-80.
7. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, et al. (2012) American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary. *Endocr Pract* 18: 269-293.
8. Langsted A, Freiberg JJ, Nordestgaard BG (2008) Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. *Circulation* 118: 2047-2056.
9. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, et al. (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. *JAMA* 298: 309-316.
10. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA* 298: 299-308.
11. Langsted A, Nordestgaard BG (2011) Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. *Clin Chem* 57: 482-489.
12. Steiner MJ, Skinner AC, Perrin EM (2011) Fasting might not be necessary before lipid screening: a nationally representative cross-sectional study. *Pediatrics* 128: 463-470.
13. Mora S, Rifai N, Buring JE, Ridker PM (2008) Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. *Circulation* 118: 993-1001.
14. Nordestgaard BG, Hilsted L, Stender S (2009) [Plasma lipids in nonfasting patients and signal values of laboratory results]. *Ugeskr Laeger* 171: 1093.

15. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 18: 499-502.
16. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ (1988) Postprandial plasma lipoprotein changes in human subjects of different ages. *J Lipid Res* 29: 469-479.
17. Schaefer EJ, Audelin MC, McNamara JR, Shah PK, Tayler T, et al. (2001) Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. *Am J Cardiol* 88: 1129-1133.
18. Rifai N, Merrill JR, Holly RG (1990) Postprandial effect of a high fat meal on plasma lipid, lipoprotein cholesterol and apolipoprotein measurements. *Ann Clin Biochem* 27: 489-493.
19. Sidhu D, Naugler C (2012) Fasting time and lipid levels in a community-based population: a cross-sectional study. *Arch Intern Med* 172: 1707-1710.
20. Rifai N, Warnick G (2006) Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors. In: Burtis C, Ashwood E, Bruns D (eds.) *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics* (4th edn.) Elsevier Saunders, Philadelphia.
21. van Dieren S, Nöthlings U, van der Schouw YT, Spijkerman AM, Rutten GE, et al. (2011) Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus. *Diabetologia* 54: 73-77.
22. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG (2008) Nonfasting triglycerides and risk of ischemic stroke in the general population. *JAMA* 300: 2142-2152.
23. Aldasouqi S, Grunberger G (2014) The traditions and risks of fasting for lipid profiles in patients with diabetes. *Postgrad Med* 126: 98-107.
24. Aldasouqi S, Sheikh A, Klosterman P, Kniestedt S, Schubert L, et al. (2011) Hypoglycemia in patients with diabetes on antidiabetic medications who fast for laboratory tests. *Diabetes Care* 34: e52.